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Abstract
We propose a new class of weighted logrank tests (WLRT) that control
the risk of concluding that a new drug is more efficacious than standard
of care, when, in fact, it is uniformly inferior. Perhaps surprisingly, this
risk is not controlled for WLRT in general. Tests from this new class can
be constructed to have high power under a delayed-onset treatment effect
scenario, as well as being almost as efficient as the standard logrank test
under proportional hazards.
Key words: Non-Proportional Hazards; Weighted Log-Rank Test; Immuno-
Oncology; Drug Regulation.
1 Introduction
The common way to analyze two-arm randomised controlled trials (RCTs) with
a time-to-event endpoint is using a logrank test (LRT) or Cox proportional haz-
ards model. The LRT is the most powerful rank-invariant test under the pro-
portional hazards assumption [1]. However, data from several recent immuno-
oncology trials have clearly violated this assumption, implying that statistical
power may be reduced, and hazard ratios may be difficult to interpret. The typ-
ical pattern is that the two treatment arms have similar survival or progression-
free survival (PFS) for an initial period (a number of months), followed by a
divergence [2]. This suggests that there is scope to improve over LRT in these
trials, and, given the importance of this class of drugs [3], the search for alter-
native methods has become very active.
Alternatives tend to fall into one of two categories: procedures based on
weighted log-rank tests ([4, 5, 6, 7]) building on the work of [8], or procedures
based on weighted differences in survival curves ([9, 10, 11, 12, 13]) building
on the work of [14]. The latter category includes restricted-mean survival time
(RMST) and landmark analysis as special cases.
This paper is about weighted log-rank tests (WLRT). First, we show that
previously proposed WLRTs may, if misinterpreted, lead to an increased risk
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of erroneously concluding that a new drug has better efficacy than standard of
care. Second, based on results from [15], we find specific choices of weights such
that this risk is always controlled. In a simulation study, we compare the power
of this new class of WLRT with the standard logrank test, previously proposed
WLRTs, and a landmark analysis.
2 Weighted logrank tests
Let S0(t) and S1(t) denote the survival probability at time t ≥ 0 on the control
and experimental treatment arms, respectively. We make a distinction between
a ‘weak’ null hypothesis that the survival distributions are the same:
Hweak0 : S1(t) = S0(t) for all t
and a ‘strong’ null hypothesis that survival on the experimental arm is
stochastically less than or equal to survival on the control arm:
Hstrong0 : S1(t) ≤ S0(t) for all t.
Let t1 < . . . < tk denote the k distinct, ordered event times. The number
at risk at time tj on arm i = 0, 1 is denoted by ni,j , with nj := n0,j + n1,j .
The number of events on arm i = 0, 1 at time tj is denoted by di,j , with
dj := d0,j + d1,j . For weights w1, . . . , wk, the weighted logrank test statistic is
U =
k∑
j=1
wj
(
d0,j − dj n0,j
nj
)
. (1)
Assuming that censoring is independent in each treatment group, under
Hweak0 , U is asymptotically normally distributed with
E(U) = 0 and Vˆ (U) =
k∑
j=1
w2j
n0,jn1,jdj(nj − dj)
n2j (nj − 1)
,
see, e.g., Chapter 7 of [16]. Statistical papers usually state that if U2/V
is larger than the (1 − α)-quantile of a one degree of freedom chi-square dis-
tribution, one may reject Hweak0 , and that this procedure has type I error α.
However, rejection of the weak null indicates nothing about the nature of the
difference in survival functions between the two groups.
The logrank test is routinely accompanied by a point estimate and a con-
fidence interval for the hazard ratio; for some estimators see [17]. When the
estimated HR and the confidence interval is below 1, it is natural to conclude
that the experimental treatment is superior.
The WLRT that have been proposed recently in immuno-oncology, for ex-
ample [6, 18, 19], have small wj for early tj , where we expect little differ-
ence between survival curves, and larger wj for later tj . ”Power” is defined as
pr(U/
√
(V ) > Φ−1(1− α/2)), and the new WLRT are shown, in delayed effect
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scenarios, to be far superior to standard LRT using this metric. Here, we must
take great caution. Figure 1 shows a scenario of a 2-arm RCT where the survival
distributions satisfy Hstrong0 , with the experimental treatment being uniformly
worse than control, but the hazard functions for the two groups are crossing. If
the weights used were wj = 0 for tj < 6 (where the hazard ratio favours control)
and wj = 1 for tj ≥ 6 (where the hazard ratio favours experimental) then it
is clear that E(U) would be strictly positive and increasing with the sample
size (number of events). If we were to claim that the experimental treatment
is more efficacious than the control when U/
√
(V ) > Φ−1(1− α/2), our risk of
false positives may far exceed α/2.
Figure 1: An example where survival on the experimental arm is stochastically
uniformly worse than on the control arm, but where the hazard functions cross,
such that some WLRT will not control the type I error rate under Hstrong0 .
3 Strong type I error control
3.1 Is the standard logrank test really unweighted?
Obviously, we want survival to be as long as possible. To test the strong null
hypothesis, any reasonable test should favour longer survival over shorter sur-
vival. Say that two random patients in the control and experimental arms,
respectively, have survival times T and T ′. If the patient on experimental treat-
ment lives longer, T ′ > T , it is an indication of a treatment benefit. If the
survival times of the two patients would be switched, we would certainly have
less reason to reject the strong null. Consequently, the p-value should increase.
Many proposed weighted logrank tests violate this principle.
To build intuition, we start by dissecting the standard logrank test, in a
simplified situation. Consider a two-arm trial with n patients per arm where
k events are observed prior to any censoring, but with the remaining 2n − k
observations censored. Also assume that there are no tied observations and let
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l0 denote the number of censored observations on the control arm. [15] show
that the standard logrank statistic U can be written as a weighted sum of the
treatment arm indicators, d0,j , minus a constant term, K > 0, times the number
of censored observations on the control arm:
k∑
j=1
d0,j
(
1−
j∑
i=1
1
2n− (i− 1)
)
−K × l0.
The weights are more commonly known as ”scores” in this context, and are
decreasing in j. Figure 2 shows an example with 2n = 200 and k = 100.
Figure 2: Score-test representation of the standard logrank test where, with 100
patients per arm, there are 100 events prior to 100 censored observations.
If an alternative test statistic of this form were to be proposed,
k∑
j=1
d0,jcj −K ′ × l0,
but where the scores cj sometimes increased, so that cj1 < cj2 when j1 < j2,
then the test would consider it ”better” to have an earlier event number j1 than
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a later j2. We think such tests should normally not be accepted
1. However,
it could be possible to keep the scores constant. In fact, this would lead to a
landmark analysis, where we compare the total number of events on each arm up
to a certain time point. Our idea, which we will elaborate in subsequent sections,
is to use constant scores cj = 1 for the initial events, then, at a certain point
in time, let cj decrease at a rate that is similar to the standard logrank test.
Since we know that the standard logrank test is the optimal rank-preserving
test under proportional hazards, our hope is that by imposing a limit on early
scores (to avoid up-weighting events where no efficacy is expected), we can find
a suitable test for a delayed-onset treatment effect.
3.2 Score statistics
Leton and Zuluaga [15] describe the relationship between logrank and score
statistics under more general censoring patterns. Let li,j denote the number of
censored observations on arm i = 0, 1 between times tj and tj+1, with lj :=
l0,j + l1,j . For scores c1, . . . , ck and C1, . . . , Ck with
∑k
j=1 djcj +
∑k
j=1 ljCj = 0,
we define the score statistic:
S =
k∑
j=1
d0,jcj +
k∑
j=1
l0,jCj .
Under Hweak0 , and assuming equal censoring distributions on the two arms,
permutation arguments (see , e.g., [20]) can be used to show that S is asymp-
totically normally distributed with
E(S) = 0,
V (S) =
N0N1
N(N − 1)
 k∑
j=1
djc
2
j +
k∑
j=1
ljC
2
j
 .
Leton and Zuluaga [15] show that for certain wj , cj and Cj the score and
logrank statistics, S and U , are equivalent. The conditions on the wj , cj and
Cj are:
Cj = −
j∑
i=1
wi
di
ni
, wj = cj − Cj (2)
or, equivalently,
wj+1 = (wj + cj+1 − cj) nj+1
nj+1 − dj+1 , wj = cj − Cj . (3)
For the standard logrank statistic, where wj = 1 for all j, we see from (2)
that the cj and Cj are uniformly non-increasing. This observation provides a
1It is possible to construct a set of scores that are not uniformly non-increasing and still
lead to strong alpha control, but it would not make sense to use this.
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heuristic argument for the strong type I error control of the standard logrank
test. Fix any survival function S0(t). First assume the weak null, that S1(t) =
S0(t) for all t ≥ 0, and let a realization of data have survival and censoring
times {T ′i} and {τi} for the experimental arm. The permutation argument [20]
shows control of the Type I Error. Now consider the strong null, S1(t) ≤ S0(t)
for all t ≥ 0. Using a coupling argument, we can map every survival time T ′i
following the distribution S0 on a (random) survival time T
′′
i ≤ T ′i such that T ′′
follows distribution S1. For the tests with non-increasing scores, changing the
realisation {T ′i} to {T ′′i } can only decrease the test statistic, leading to a larger
p-value. This demonstrates strong alpha control.
For some other WLRT, however, the scores are not non-increasing. Take the
example above where wj = 0 for tj < 6 and wj = 1 for tj ≥ 6. Here cj = 0 for
tj < 6 and cj is close to 1 for the first tj greater than 6.
3.3 Modestly weighted logrank tests (mWLRT)
The heuristic argument above suggests a new class of WLRT that controls the
type I error rate under Hstrong0 . The idea is to start with the score statistic
formulation of the WLRT and fix cj = 1 for tj < t
∗. We can use (3) to derive
w1, . . . , wj∗ and C1, . . . , Cj∗ , where tj∗ := min tj : tj < t∗. Thereafter, however,
we fix wj = wj∗ for j = j
∗ + 1, . . . , k and use (2) to derive cj∗+1, . . . , ck and
Cj∗+1, . . . , Ck. As an example, consider a 2-arm trial with n = 100 per arm,
where 100 events are observed prior to any censored observations, with the
remaining 100 patients censored. Further suppose that 30 out of the 100 events
are observed prior to t∗. The resulting scores are shown in Figure 3. We call this
class of tests ”modestly weighted logrank tests (mWLRT)” because the range
of logrank weights is far smaller than in previous proposals.
The larger t∗, the lower the relative weight given to early events, which is a
good thing if we expect a delayed effect. On the other hand, if t∗ is too large
then later events will get very high wj , which may be inefficient. The choice of
t∗ involves a trade-off of these two things. We can use simulations to guide us.
4 Simulation study
4.1 Scenarios
We consider a two-arm RCT with 100 patients per arm, recruited at a uniform
rate over 12 months. On the control arm, survival times are exponentially
distributed with median 15 months. Data cut-off is at a calendar time of 36
months after the start of the study, at which point any patients still alive are
censored. The following four scenarios differ only according to the survival
distribution on the experimental arm.
I. Weak null hypothesis: survival on the experimental arm is exponentially
distributed with median 15 months, i.e., with rate log(2)/15 = 0.046
6
Figure 3: Score-test and logrank-test representations of a modestly-weighted
logrank test (mWLRT). Based on a 2-arm trial with n = 100 per arm, where 100
events are observed prior to any censored observations, with 30 events observed
prior to t∗, and with 100 observations censored.
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II. Strong null hypothesis: survival on the experimental arm follows a 2-piece
exponential distribution. For the first 6 months the rate is log(2)/9 =
0.077; thereafter the rate is 0.04.
III. New treatment efficacious (PH): survival on the experimental arm is ex-
ponentially distributed with median 24 months, i.e., with rate log(2)/24 =
0.029
IV. New treatment efficacious (NPH): survival on the experimental arm fol-
lows a 2-piece exponential distribution. For the first 6 months the rate is
log(2)/15 = 0.046; thereafter the rate is log(2)/30 = 0.023.
The survival curves corresponding to these scenarios are shown in Figure 4.
Figure 4: Simulation study scenarios.
4.2 Methods
We compare three methods:
1. WLRT(t∗), where t∗ ∈ {0, 6}.
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2. mWLRT(t∗), where t∗ ∈ [3, 30].
3. Landmark(t∗), where t∗ ∈ [15, 30].
Here, WLRT(t∗), refers to a weighted logrank test where wj = 0 if tj < t∗
and wj = 1 otherwise. So that WLRT(0) is the standard logrank test.
A landmark analysis at time t uses
Sˆ1(t)− Sˆ0(t)√
var
{
Sˆ1(t)
}
+ var
{
Sˆ0(t)
}
as the standardized test statistic, based on Kaplan-Meier estimation.
4.3 Results
Simulation results, based on 10,000 replications, are presented in Figure 5.
Under the weak null hypothesis S1(t) = S0(t) all methods control the one-
sided type I error rate at the nominal 0.025 level.
Under scenario II, where the survival curves are contained inHstrong0 , WLRT(6)
has pr(U/
√
V > Φ−1(1− 0.025)) substantially greater than 0.025. For all other
methods, this probability is less than 0.025.
Under scenario III, where the hazards are proportional, the standard logrank
test has the highest power. However, the mWLRT(t∗) are very close, suggest-
ing that tests from this new class lose very little efficiency under proportional
hazards. In contrast, WLRT(6), which gives zero weight to early events, is
substantially less powerful, as are the landmark analyses.
Under scenario IV it is WLRT(6) that is optimal. However, the new tests do
substantially better than the standard logrank test, and are competitive with
the best landmark analysis.
We can also express these results in terms of relative efficiency. For example,
compared to the standard logrank test, mWLRT(18) has a relative efficiency of
100×
{
Φ−1(0.975) + Φ−1(0.748)
Φ−1(0.975) + Φ−1(0.766)
}
= 96%
under the proportional hazards scenario, and
100×
{
Φ−1(0.975) + Φ−1(0.796)
Φ−1(0.975) + Φ−1(0.697)
}
= 127%
under the nonproportional hazards scenario. In contrast, the best landmark
analysis at t∗ = 27 has relative efficiency compared to the standard logrank test
of 87% under proportional hazards, and 114% under nonproportional hazards.
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Figure 5: Power and type 1 error of weighted logrank and landmark analyses
under the four scenarios from Figure 4.
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5 Discussion
Evaluating a treatment is much more complicated than checking whether the
p-value is less than 5%. In this section, we will discuss a number of topics
related to the evaluation of drugs with potentially non-proportional hazards: 1)
one-sided vs. two-sided testing; 2) Is rejecting the strong null hypothesis enough
to show a real benefit?; 3) How can efficacy be estimated?; 4) Are there other
promising tests?; 5) Further work.
In most standard situations, the relationship between one-sided and two-
sided tests is trivial. Often, there is one key parameter of interest, e.g. cure rate,
and if the null is rejected, it is obvious whether the conclusion should be that
the new treatment has an efficacy advantage or disadvantage. This poses a risk
that scientists do not recognise when one-sided testing is crucial. Although truly
two-sided null hypotheses may be of interest in some other applications, they are
virtually never of value for the primary analysis of confirmatory clinical trials.
We have to show that the new drug has at least some efficacy advantage, not
that it is different in an unspecified way. Our recommendation is therefore that
regulatory guidance documents should consistently require one-sided hypothesis
tests.
When time-to-event data are analysed, we are trying to compare two infinite-
dimensional survival curves. Unless in a non-inferiority setting, we think that
the minimal requirement for a new drug is that the strong null hypothesis of
uniformly shorter (progression-free) survival can be rejected. Unfortunately, this
is only concluding that survival is better at some time points; without further
assumptions it is impossible to conclude that that all patients will benefit or
that the survival rate will not be worse at some point in time. These issues are
inherent in the experimental setting.
We do not argue that the standard logrank test or Cox regression are invalid
if hazards are non-proportional, but these tests have a clear benefit only if
hazards are proportional or at least if that is a good approximation. As we
have seen, the standard logrank test, which is often labelled ”unweighted”, does
in fact weight observations differently and this particular weighting can lead to
a very inefficient inference in the case of non-proportional hazards. Similarly,
the estimated hazard ratio that comes with the standard methods only has a
clear utility for (approximately) proportional hazards, and even then we still
require supplementary measures. A hazard ratio of 0.5 has a different meaning
clinically when median survival is 3 months compared to when it is 3 years.
We argue that mWLRT have robust power when we expect a delayed sep-
aration of survival curves, as well as providing strong control of the type 1
error rate. For WLRT it is possible to construct an estimate of a weighted
hazard ratio [6], but this will be equally, if not more, difficult to interpret as
the standard hazard ratio estimate under non-proportional hazards. Therefore,
additional measures will always be required. It is common to complement an
analysis with estimated median survival. This is relatively easy to interpret,
but ignores much of the information, and the full Kaplan-Meier curves will add
information. The mean survival is clinically relevant and often a key parameter
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for reimbursement.
Tests based on restricted mean survival hold some promise, although cen-
soring adds variability and the cutoff time for inclusion in the restricted mean
is somewhat arbitrary. It may be useful to consider parametric approaches, tai-
lored to likely survival distributions. We think that a sponsor should pre-specify
the analysis and in that process try to predict trial outcome and uncertainties.
With a fixed alternative hypothesis, it could in principle be possible to optimize
the test across the different approaches that have been suggested. In practice,
it is important also to consider the robustness of different inference options.
Assurance, expected power over a distribution of scenarios, can be one useful
operating characteristic.
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